Drug Trial Radar · NCT04704921
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
671
Actual
Start
Dec 29, 2020
Primary completion
Dec 2026
Study completion Nov 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- REGENXBIO Inc.
- First posted
- Jan 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to maintain or prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every 4 to 16 weeks in frequency, to maintain efficacy. Due to the burden of these treatments, patients often experience a decline in vision with reduced frequency of treatment over time.
Conditions
- AMD
- nAMD
- Wet Age-related Macular Degeneration
- wAMD
- Wet AMD
- CNV
- Neovascular AMD
- Neovascular Age-related Macular Degeneration
- Choroidal Neovascularization
Interventions
ABBV-RGX-314Genetic
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
ABBV-RGX-314Genetic
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
Ranibizumab (LUCENTIS®)Biological
0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection approximately every 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in Best Corrected Visual Acuity (BCVA)Time frame: At Week 54
- Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEsTime frame: Week 50
Locations
89 sites in 1 country. Site status is shown where the registry gives one.
Retinal Research Institute /ID# 256019
Phoenix, Arizona
Barnet Dulaney Perkins Eye Center - Sun City /ID# 256055
Sun City, Arizona
University of Arkansas for Medical Sciences /ID# 271290
Little Rock, Arkansas
Retina Vitreous Assoc Med Grp /ID# 256299
Beverly Hills, California
Retinal Diagnostic Center /ID# 256137
Campbell, California
The Retina Partners - Encino /ID# 256054
Encino, California
Retina Consultants of Orange County /ID# 256152
Fullerton, California
Salehi Retina Institute /ID# 263485
Huntington Beach, California
UC Irvine/Gavin Herbert Eye Institute /ID# 256145
Irvine, California
Northern California Retina Vitreous Associates Medical Group, Inc /ID# 256298
Mountain View, California
UCLA Doheny Eye Center /ID# 256120
Pasadena, California
California Eye Specialists Medical Group Inc. /ID# 256079
Pasadena, California
Retina Consultants of San Diego /ID# 256021
Poway, California
Retinal Consultants Medical Group /ID# 256047
Sacramento, California
West Coast Retina /ID# 256448
San Francisco, California
University of California, San Francisco /ID# 256130
San Francisco, California
Orange County Retina Medical Group /ID# 256073
Santa Ana, California
California Retina Consultants - Santa Barbara /ID# 256017
Santa Barbara, California
Retina Consultants of Southern Colorado /ID# 256069
Colorado Springs, Colorado
Southwest Retina Research Center /ID# 256136
Durango, Colorado
Colorado Retina Associates /ID# 256121
Lakewood, Colorado
Retina Group of New England - Waterford /ID# 256071
Waterford, Connecticut
Advanced Research, LLC /ID# 275451
Deerfield Beach, Florida
Vitreoretinal Associates, P.A. /ID# 256150
Gainesville, Florida
Florida Retina Consultants /ID# 265661
Lakeland, Florida
Bascom Palmer Eye Institute - University of Miami /ID# 256072
Miami, Florida
Retina Specialty Institute /ID# 256153
Pensacola, Florida
Retina Vitreous Associates of Florida - St. Petersburg /ID# 256050
St. Petersburg, Florida
Southern Vitreoretinal Associates /ID# 256158
Tallahassee, Florida
Southeast Retina Center /ID# 256022
Augusta, Georgia
Georgia Retina - Marietta /ID# 256142
Marietta, Georgia
Marietta Eye Clinic /ID# 268163
Marietta, Georgia
Thomas Eye Group PC /ID# 268159
Sandy Springs, Georgia
Retina Consultants of Hawaii /ID# 256049
‘Aiea, Hawaii
University of Illinois at Chicago /ID# 256300
Chicago, Illinois
University Retina and Macula Associates /ID# 256078
Lemont, Illinois
University Retina and Macula Associates /ID# 256077
Oak Forest, Illinois
Springfield Clinic /ID# 266225
Springfield, Illinois
Retina Partners Midwest, PC /ID# 256045
Indianapolis, Indiana
John-Kenyon American Eye Institute -New Albany /ID# 256065
New Albany, Indiana
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.